Diabetes News

Adults with overweight or obesity lost more weight with the GIP/GLP-1 dual agonist tirzepatide than the GLP-1 receptor agonist semaglutide, according to findings published in JAMA Internal Medicine.

People with type 2 diabetes who use a GLP-1 receptor agonist have a lower risk for 10 types of obesity-associated cancer compared with those who use insulin, according to data published in JAMA Network Open.

Adults with diabetes or obesity using semaglutide may have an increased risk for nonarteritic anterior ischemic optic neuropathy, a common form of optic neuropathy, according to data published in JAMA Ophthalmology.

Women with type 2 diabetes diagnosed with hypertension at younger than age 50 years have an increased risk for cardiovascular disease and could benefit from intensive antihypertension therapy according to data published in Diabetes Care.

AI in diabetes care is becoming more popular with various potential benefits for patients and clinicians as well as important challenges to keep in mind, according to a conversation between two diabetes experts.

ORLANDO — In this video exclusive, James R. Gavin III, MD, PhD, Healio | Endocrine Today co-editor, talks with Edward C. Chao, DO, about the importance of not worsening disparities with the implementation of AI in diabetes care.

ORLANDO — In this video exclusive, James R. Gavin III, MD, PhD, Healio | Endocrine Today co-editor, talks with Edward C. Chao, DO, about important considerations for using AI in clinical practice.

ORLANDO — In this video exclusive, James R. Gavin III, MD, PhD, Healio | Endocrine Today co-editor, talks with Edward C. Chao, DO, about the benefits and challenges of using AI in diabetes care.

CHICAGO — A greater intake of ultraprocessed foods, or UPFs, did not significantly increase the risk for type 2 diabetes in middle-aged adults, according to a study presented at NUTRITION.

Published results showed exercise in combination with glucagon-like peptide-1 receptor agonist treatment may be an effective weight loss strategy that preserves clinically relevant site-specific bone mineral density.